Sirtuin Acetylation and Deacetylation: a Complex Paradigm in Neurodegenerative Disease

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2021 Apr 20

PMID 33877561

Citations 23

Authors

Heena Khan

Palak Tiwari

Amarjot Kaur

Thakur Gurjeet Singh

Affiliations

Soon will be listed here.

Abstract

Sirtuins are the class III of histone deacetylases that depend on nicotinamide adenine dinucleotide for their activity. Sirtuins can influence the progression of neurodegenerative disorders by switching between deacetylation and acetylation processes. Histone acetylation occurs when acetyl groups are added to lysine residues on the N-terminal part of histone proteins. Deacetylation, on the other hand, results in the removal of acetyl groups. Pharmacological modulation of sirtuin activity has been shown to influence various neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and amyotrophic lateral sclerosis. In this review, mechanistic perspective of sirtuins has been discussed in anti-inflammatory, antiapoptotic, and neuroprotective effects in various disorders. We have discussed the structure, neurobiology, and physiology of sirtuins in neurodegenerative disease. Recent preclinical and clinical studies and their outcome have also been elucidated. The aim of this review is to fill in the gaps in our understanding of sirtuins' role in histone acetylation and deacetylation in all neurodegenerative diseases. Here, we emphasized on reviewing all the studies carried out in various labs depicting the role of sirtuin modulators in neuroprotection and highlighted the ideas that can be considered for future perspectives. Taken together, sirtuins may serve as a promising therapeutic target for the treatment of neurodegenerative disorders.

Citing Articles

Malnutrition Risk in Older Adults: Evaluating the Diagnostic Relevance of Serum Biomarkers: SIRT-1, CCK-8, Melatonin, and Total Antioxidant Capacity (TAC).

Kujawowicz K, Mironczuk-Chodakowska I, Cyunczyk M, Witkowska A Nutrients. 2025; 17(4).

PMID: 40005054 PMC: 11858257. DOI: 10.3390/nu17040726.

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.

Toader C, Tataru C, Munteanu O, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2024; 25(23.

PMID: 39684324 PMC: 11641752. DOI: 10.3390/ijms252312613.

Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease.

Kaur P, Khan H, Grewal A, Dua K, Singh S, Gupta G CNS Neurol Disord Drug Targets. 2024; 24(3):196-207.

PMID: 39473249 DOI: 10.2174/0118715273321002240919102841.

Rutin Ameliorates ALS Pathology by Reducing SOD1 Aggregation and Neuroinflammation in an SOD1-G93A Mouse Model.

Du X, Dong Q, Zhu J, Li L, Yu X, Liu R Int J Mol Sci. 2024; 25(19).

PMID: 39408720 PMC: 11477130. DOI: 10.3390/ijms251910392.

Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease.

Mishra T, Singh S, Singh T Cell Mol Neurobiol. 2024; 44(1):53.

PMID: 38960968 PMC: 11222187. DOI: 10.1007/s10571-024-01471-8.

References

Canto C, Auwerx J . Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol Rev. 2011; 64(1):166-87. PMC: 3616312. DOI: 10.1124/pr.110.003905. View

Wang Y, He J, Liao M, Hu M, Li W, Ouyang H . An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Eur J Med Chem. 2018; 161:48-77. DOI: 10.1016/j.ejmech.2018.10.028. View

Han S . Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol. 2009; 5(3):120-5. PMC: 2760716. DOI: 10.3988/jcn.2009.5.3.120. View

Gomes P, Leal H, Mendes A, Reis F, Cavadas C . Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases. Trends Pharmacol Sci. 2019; 40(12):1021-1039. DOI: 10.1016/j.tips.2019.09.003. View

Herskovits A, Guarente L . Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 2013; 23(6):746-58. PMC: 3674397. DOI: 10.1038/cr.2013.70. View

Walker M, Tian R . NAD(H) in mitochondrial energy transduction: implications for health and disease. Curr Opin Physiol. 2020; 3:101-109. PMC: 7112453. DOI: 10.1016/j.cophys.2018.03.011. View

Connell N, Houtkooper R, Schrauwen P . NAD metabolism as a target for metabolic health: have we found the silver bullet?. Diabetologia. 2019; 62(6):888-899. PMC: 6509089. DOI: 10.1007/s00125-019-4831-3. View

Canto C, Menzies K, Auwerx J . NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015; 22(1):31-53. PMC: 4487780. DOI: 10.1016/j.cmet.2015.05.023. View

Sosnowska B, Mazidi M, Penson P, Gluba-Brzozka A, Rysz J, Banach M . The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017; 265:275-282. DOI: 10.1016/j.atherosclerosis.2017.08.027. View

10.

Nogueiras R, Habegger K, Chaudhary N, Finan B, Banks A, Dietrich M . Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012; 92(3):1479-514. PMC: 3746174. DOI: 10.1152/physrev.00022.2011. View

11.

Zschoernig B, Mahlknecht U . SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun. 2008; 376(2):251-5. DOI: 10.1016/j.bbrc.2008.08.137. View

12.

Gillum M, Erion D, Shulman G . Sirtuin-1 regulation of mammalian metabolism. Trends Mol Med. 2010; 17(1):8-13. PMC: 3123438. DOI: 10.1016/j.molmed.2010.09.005. View

13.

Zeng L, Chen R, Liang F, Tsuchiya H, Murai H, Nakahashi T . Silent information regulator, Sirtuin 1, and age-related diseases. Geriatr Gerontol Int. 2009; 9(1):7-15. DOI: 10.1111/j.1447-0594.2008.00504.x. View

15.

Langley B, Sauve A . Sirtuin deacetylases as therapeutic targets in the nervous system. Neurotherapeutics. 2013; 10(4):605-20. PMC: 3805877. DOI: 10.1007/s13311-013-0214-5. View

16.

Gomes P, Outeiro T, Cavadas C . Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism. Trends Pharmacol Sci. 2015; 36(11):756-768. DOI: 10.1016/j.tips.2015.08.001. View

17.

Pillai V, Sundaresan N, Jeevanandam V, Gupta M . Mitochondrial SIRT3 and heart disease. Cardiovasc Res. 2010; 88(2):250-6. PMC: 2952535. DOI: 10.1093/cvr/cvq250. View

18.

Scher M, Vaquero A, Reinberg D . SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007; 21(8):920-8. PMC: 1847710. DOI: 10.1101/gad.1527307. View

19.

Anekonda T, Reddy P . Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem. 2005; 96(2):305-13. DOI: 10.1111/j.1471-4159.2005.03492.x. View

20.

Ahuja N, Schwer B, Carobbio S, Waltregny D, North B, Castronovo V . Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem. 2007; 282(46):33583-33592. DOI: 10.1074/jbc.M705488200. View

21.

Huang G, Zhu G . Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer. Onco Targets Ther. 2018; 11:3395-3400. PMC: 6001835. DOI: 10.2147/OTT.S157724. View